SFI
AGRX

Susquehanna Fundamental Investments’s Agile Therapeutics AGRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-326
Closed -$5K – 1581
2022
Q3 		$5K Buy
+326
New +$8.02K ﹤0.01% 1424

Other funds holding AGRX

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Susquehanna Fundamental Investments's AGRX Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Agile Therapeutics (AGRX) in Q4 2022, closing a stake of 326 shares — an estimated $5K sold.

Susquehanna Fundamental Investments first reported a position in AGRX in Q3 2022 and held it in 1 quarter. The position peaked at $5K in Q3 2022. 26 funds tracked by Wall St. Rank hold AGRX as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Agile Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 326 Agile Therapeutics shares in Q4 2022, an estimated $5K.
  • Susquehanna Fundamental Investments first reported a position in Agile Therapeutics in Q3 2022 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Agile Therapeutics position peaked at $5K in Q3 2022.
  • 26 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.